コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 treated with radiotherapy (RT) after breast-conserving surgery.
2 nodes and had completed mastectomy or breast-conserving surgery.
3 changing from radical nephrectomy to nephron-conserving surgery.
4 andard whole-breast irradiation after breast-conserving surgery.
5 ng of TAM and radiotherapy (RT) after breast-conserving surgery.
6 in stage II BC patients treated with breast conserving surgery.
7 .37) were the strongest predictors of breast-conserving surgery.
8 stics were associated with the use of breast-conserving surgery.
9 esponded and 48% underwent successful breast-conserving surgery.
10 was given to 86% of patients who had breast-conserving surgery.
11 e as likely as other women to undergo breast-conserving surgery.
12 ss likely than other women to undergo breast-conserving surgery.
13 ransient effect on the rate of use of breast-conserving surgery.
14 All had had breast-conserving surgery.
15 influences local recurrence following breast-conserving surgery.
16 fit from neoadjuvant therapy enabling breast-conserving surgery.
17 traoperative margin assessment during breast-conserving surgery.
18 nical application of gGlu-HMRG during breast-conserving surgery.
19 ajority of patients (76.1%) underwent breast-conserving surgery.
20 breast tissue is an important step in breast-conserving surgery.
21 tion of residual cancer tissue during breast-conserving surgery.
22 bmitted for surgery, and 10 underwent breast-conserving surgery.
23 r intraoperative margin assessment in breast-conserving surgeries.
24 tential intraoperative use in guiding breast-conserving surgeries.
26 erienced no recurrence, 963 underwent breast-conserving surgery, 263 mastectomy without reconstructio
27 vasive breast cancer, 59.6% underwent breast-conserving surgery, 33.4% underwent unilateral mastectom
28 vasive breast cancer, 59.6% underwent breast-conserving surgery, 33.4% underwent unilateral mastectom
32 omissions of radiation therapy after breast-conserving surgery, adjuvant chemotherapy after resectio
33 00-12.50 Gy/4-5 fractions]) following breast-conserving surgery administered in community-based and a
34 pport the treatment of MO tumors with breast conserving surgery after a detailed clinical evaluation.
35 mpact of tumor biology on the rate of breast-conserving surgery after neoadjuvant chemotherapy has no
36 on, we determined whether the rate of breast-conserving surgery after the legislation was different f
38 xamined the trend over time in use of breast-conserving surgery among patients in four sites (Connect
39 in both states and the correlates of breast-conserving surgery among women eligible for the procedur
40 to 1.73), but less likely to undergo breast-conserving surgery among women undergoing definitive sur
41 ative whole-breast radiotherapy after breast-conserving surgery and adjuvant endocrine treatment resu
42 e breast cancer who were treated with breast-conserving surgery and adjuvant systemic therapy to unde
43 ults of studies of radiotherapy after breast-conserving surgery and after mastectomy, and an interpre
44 paclitaxel chemotherapy, followed by breast-conserving surgery and axillary lymph node dissection, w
46 treatment of DCIS of the breast using breast-conserving surgery and definitive breast irradiation.
47 years (mean, 55.9 years) treated with breast-conserving surgery and irradiation (n = 183) underwent a
49 9 through 2011, to determine rates of breast-conserving surgery and pCR after chemotherapy by approxi
50 ast cancers have the highest rates of breast-conserving surgery and pCR after neoadjuvant chemotherap
51 or younger at diagnosis treated with breast-conserving surgery and radiation therapy (> or = 60 Gy)
58 ot both, were permitted), who had had breast-conserving surgery and were receiving adjuvant endocrine
59 an half (56%) of the women who had fertility-conserving surgery and who have been in remission at lea
61 carcinoma in situ (DCIS) treated with breast-conserving surgery and whole-breast irradiation (WBRT).
62 d, 20% do not receive radiation after breast-conserving surgery, and 30% to 70% of women with lymph n
63 the likelihood that women will choose breast-conserving surgery, and enhances patient knowledge of tr
64 re DCIS (no microinvasion), underwent breast-conserving surgery, and received WBRT with or without th
66 f persons undergoing cholecystectomy, breast-conserving surgery, anterior cruciate ligament reconstru
67 mal mortality, recurrence rates after breast-conserving surgery are significant, and half are invasiv
68 e (n = 124), 44% of patients received breast-conserving surgery (BCS) after anastrozole compared with
69 tients with invasive cancer receiving breast-conserving surgery (BCS) and among patients undergoing m
70 adical mastectomy (MRM) compared with breast-conserving surgery (BCS) and radiation therapy (RT).
71 99, demonstrated that tamoxifen after breast-conserving surgery (BCS) and radiotherapy for ductal car
72 breast cancer patients, treated with breast-conserving surgery (BCS) and whole-breast irradiation (W
73 f Health Consensus Statement in 1990, breast-conserving surgery (BCS) became more common while mastec
74 may decrease the reoperation rate in breast-conserving surgery (BCS) compared with rates after surge
75 ists in the use of radiotherapy after breast-conserving surgery (BCS) for ductal carcinoma in situ (D
76 psilateral breast events (IBEs) after breast-conserving surgery (BCS) for ductal carcinoma in situ (D
77 ase inhibitor (AI) treatment promotes breast-conserving surgery (BCS) for estrogen receptor (ER)-posi
78 d for the treatment of DCIS; however, breast-conserving surgery (BCS) has been adopted as the treatme
80 These 25,000 women included 7300 with breast-conserving surgery (BCS) in trials of radiotherapy (gene
88 ume surgeons were more likely to have breast-conserving surgery (BCS) than those managed by low-volum
90 CI, 1.00 to 1.85), and have received breast-conserving surgery (BCS) without radiotherapy (v mastect
91 st for early stage breast cancer: (1) breast conserving surgery (BCS), (2) mastectomy with reconstruc
93 ing NAC, adjuvant chemotherapy (aCT), breast conserving surgery (BCS), bilateral mastectomy (BLM), an
94 he risk of local recurrence following breast-conserving surgery (BCS), even in "low-risk" populations
103 racteristics, treatments (mastectomy, breast-conserving surgery [BCS] with radiation therapy or alone
107 gnosed breast cancer who were offered breast-conserving surgery consented from September 2006 to Nove
110 are comparable to outcomes seen after breast-conserving surgery followed by standard whole-breast irr
113 d 50 years or older who had undergone breast-conserving surgery for unifocal invasive ductal adenocar
114 women from receiving the benefits of breast-conserving surgery, forcing them to choose a mastectomy
123 r the procedure, nearly 75% underwent breast-conserving surgery in Massachusetts and nearly half did
125 ing multicatheter brachytherapy after breast-conserving surgery in patients with early breast cancer
128 tion of all women who were treated by breast-conserving surgery increased, and because this approach
132 east cancer, standard treatment after breast-conserving surgery is adjuvant whole-breast radiotherapy
134 The surgical margin status after breast-conserving surgery is considered the strongest predictor
137 er, or ductal carcinoma in situ (when breast-conserving surgery is planned) or are pregnant should no
138 ammatory breast cancer, or DCIS (when breast-conserving surgery is planned) or are pregnant should no
139 ing fact about local recurrence after breast-conserving surgery is that most occurs in the area of br
142 fter 10 years, but the risk following breast-conserving surgery (lumpectomy) has yet to be determined
145 Fifty-nine percent of women underwent breast-conserving surgery, of whom 81% received radiation thera
146 n undergoing an inappropriate form of breast-conserving surgery (omission of radiotherapy, axillary n
147 through 79 years of age who underwent breast-conserving surgery or mastectomy for local or regional b
148 on aid were 25% more likely to choose breast-conserving surgery over mastectomy (risk ratio, 1.25; 95
149 no more likely than others to undergo breast-conserving surgery (P >.2), but these women were more sa
150 DeltaBF cutoff = -30%; P = 0.03), non-breast-conserving surgery (P = 0.04), and the absence of a path
153 surgical therapy, radiotherapy after breast-conserving surgery, radiation therapy after mastectomy,
154 women with breast cancer who undergo breast-conserving surgery receive whole-breast irradiation.
155 randomized trials, radiotherapy after breast-conserving surgery reduced mortality from both breast ca
156 Medicare coverage had lower rates of breast-conserving surgery than other women (43.2% vs. 49.2%; ad
158 urgically treated patients (including breast-conserving surgery), the CPM rate increased by 148% from
159 t DCIS (excluding patients undergoing breast-conserving surgery), the CPM rate increased by 188% from
160 </= 3 cm were randomly assigned after breast-conserving surgery to 3D-CRT APBI (38.5 Gy in 10 fractio
162 al trends between patients undergoing breast-conserving surgery, unilateral mastectomy, and CPM.
163 al trends between patients undergoing breast-conserving surgery, unilateral mastectomy, and CPM.
164 radiation); axillary dissection; and breast-conserving surgery versus mastectomy among women undergo
166 erall rate of radiation therapy after breast-conserving surgery was 80% in the quality improvement pr
167 bservational data, radiotherapy after breast-conserving surgery was associated with much larger morta
170 of patients undergoing mastectomy and breast conserving surgery was performed from the National Surgi
175 ductal carcinoma in situ treated with breast-conserving surgery were centrally randomised to either w
176 ve ductal breast carcinoma undergoing breast-conserving surgery were enrolled from 28 centres in nine
177 primary breast cancer ineligible for breast-conserving surgery were randomly assigned to 4 months of
180 s operable and increases the rates of breast-conserving surgery, while achieving similar long-term cl
181 oximately 3% of patients treated with breast-conserving surgery will have an in-breast local recurren
182 published world medical literature on breast-conserving surgery with and without postoperative irradi
183 tomy with axillary node dissection or breast-conserving surgery with axillary node dissection and rad
184 ges I or II breast cancer, excised by breast conserving surgery with negative margins, were eligible
185 om patients who had been treated with breast-conserving surgery with or without postoperative radiati
187 between 1998 and 2007, who underwent breast-conserving surgery with radiation (breast-conserving the
188 between 1998 and 2007, who underwent breast-conserving surgery with radiation (breast-conserving the
189 CI, 1.02 to 1.73) more likely to get breast-conserving surgery with radiation than other types of tr
190 d on National Guidelines as receiving breast-conserving surgery with radiation therapy and axillary n
191 of definitive surgery (mastectomy or breast-conserving surgery with radiation v breast-conserving su
193 RO) guideline on surgical margins for breast-conserving surgery with whole-breast irradiation in stag
194 atic SLNs who are planning to undergo breast-conserving surgery with whole-breast radiotherapy should
195 o metastatic SLNs planning to undergo breast-conserving surgery with whole-breast radiotherapy should
196 carcinoma in situ (DCIS) treated with breast-conserving surgery without adjuvant radiation therapy (R
197 s lower (3.7% vs 5.0%; P < .001), and breast-conserving surgery without other treatment was more freq
198 t-conserving surgery with radiation v breast-conserving surgery without radiation); axillary dissecti
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。